Lost to follow up and clinical outcomes of HIV adult patients on antiretroviral therapy in care and treatment centres in Tanga City, north-eastern Tanzania.

Scaling up of Antiretroviral (ARV) drugs is crucial and should be a perpetual venture in developing countries in-order to increase the survival period of HIV/AIDS individuals. In Tanzania, information on the rate of patients considered as lost to follow up during treatment with ARVs is scarce. The objective of this study was to determine the rate of lost to follow up and treatment outcome among patients attending two care and treatment clinics (CTCs) in Tanga City in north-eastern Tanzania. A descriptive observational study was carried out on cohorts from Tanga AIDS Working Group and Bombo Regional Hospital. The total number of patients identified as "lost to follow up" were 89 of which 14 (15.7%) died. Among those who died, 3 (21.4%) died between the second week and 3 months after ARV initiation. Of those still alive (84.3%; 75/89), 25% (19/75) were still on ARVs, whereas 47 (62.7%) self transferred to other CTCs. Proper patient documentation with actual residence address is a crucial aspect for adherence. Similarly, frequent prompt tracing of patient should be part of any drug interventional programme linking facility and communities.

[1]  C. Yiannoutsos,et al.  Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. , 2010, Bulletin of the World Health Organization.

[2]  S. Rosen,et al.  Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review , 2010, Tropical medicine & international health : TM & IH.

[3]  J. Nachega,et al.  Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities , 2010, Current opinion in HIV and AIDS.

[4]  D. Bennett,et al.  Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania , 2008, Antiviral therapy.

[5]  D. Bennett,et al.  Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006 , 2008, Antiviral therapy.

[6]  Sydney Rosen,et al.  Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic Review , 2007, PLoS medicine.

[7]  G. Harms,et al.  Risk factors for treatment denial and loss to follow‐up in an antiretroviral treatment cohort in Kenya , 2007, Tropical medicine & international health : TM & IH.

[8]  R. Succi,et al.  AIDS by mother-to-child transmission: survival analysis of cases followed from 1983 to 2002 in different regions of Brazil. , 2007, Cadernos de saude publica.

[9]  I. Buchan,et al.  Adherence to HAART : A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators , 2006 .

[10]  N. Ford,et al.  Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment , 2006, The Lancet.

[11]  J. Sterne,et al.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.

[12]  Kara Wools-Kaloustian,et al.  Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya , 2006, AIDS.

[13]  D. Hamer,et al.  No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. , 2005, AIDS.

[14]  K. Pallangyo,et al.  Dropouts in a Long‐Term Follow‐Up Study Involving Voluntary Counseling And HIV Testing: Experience From a Cohort of Police Officers in Dar Es Salaam, Tanzania , 2002, Journal of acquired immune deficiency syndromes.

[15]  A. Mocroft,et al.  Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. , 1997, International journal of epidemiology.

[16]  M. White.  No room for complacency , 1977, British medical journal.